Aktiesnakken — Marts 2010
-
og jo bedre det går for ritux jo bedre går det for arzerra!
-
100% hvis egfr går hjem burde genmab går langt over 150
-
fordi jo flere der får ritux, jo flere er refrac og derved arzerra kunder
-
lad nu ikke de issues overskygge det faktum, at der et 4 måder at undgå kap udvidelse på
-
-
uptake er 8 kvartaler
-
såvidt jeg lige kan se
-
de har sagt aktien op for 2 opjusteringer i år, måske 3
-
2012 bliver et dejligt år at have genmab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind